Heck Capital Advisors LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 490 shares of the medical device company’s stock, valued at approximately $38,000.
A number of other large investors have also made changes to their positions in DXCM. Versant Capital Management Inc bought a new position in DexCom during the 4th quarter worth about $25,000. Riverview Trust Co increased its holdings in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares in the last quarter. RPg Family Wealth Advisory LLC bought a new position in DexCom during the 3rd quarter worth about $57,000. Covestor Ltd increased its holdings in DexCom by 53.7% during the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after purchasing an additional 335 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB increased its holdings in DexCom by 46.7% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after purchasing an additional 265 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.
Analysts Set New Price Targets
A number of equities analysts have issued reports on the company. Oppenheimer lowered their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Raymond James reduced their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Canaccord Genuity Group increased their price objective on shares of DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Finally, Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $98.41.
DexCom Stock Up 0.3 %
Shares of DXCM opened at $87.05 on Tuesday. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The firm’s 50 day moving average is $80.77 and its 200-day moving average is $75.94. The stock has a market capitalization of $34.00 billion, a PE ratio of 52.13, a P/E/G ratio of 2.23 and a beta of 1.14. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.
Insider Transactions at DexCom
In related news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 42,342 shares of company stock valued at $3,628,069. 0.30% of the stock is currently owned by company insiders.
DexCom Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Read More
- Five stocks we like better than DexCom
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- How to Invest in Small Cap Stocks
- Comparing and Trading High PE Ratio Stocks
- These Are the Dividend Stocks Insiders Bought in January
- What is the Nikkei 225 index?
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.